TWi Biotechnology (ROCO:6610) Payments of Debt: NT$-10.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6610 TWi Biotechnology Inc ROCO:6610
31 GF Score
Price NT$26.55
! 2 Warning Signs
View Full Analysis

What is TWi Biotechnology Payments of Debt?

TWi Biotechnology ROCO:6610 +0.57% 31 Payments of Debt is NT$-10.00 Mil as of Dec. 2025. GuruFocus rates ROCO:6610 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

TWi Biotechnology's Payments of Debt for the six months ended in Dec. 2025 was NT$0.00 Mil.

TWi Biotechnology's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-10.00 Mil.

TWi Biotechnology Payments of Debt Related Terms

TWi Biotechnology Payments of Debt Historical Data

* Premium members only.

The historical data trend for TWi Biotechnology's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TWi Biotechnology Payments of Debt Chart

TWi Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.60 0.00 0.00 0.00 -10.00

TWi Biotechnology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -10.00 0.00
ROCO:6610
31GF Score
TWi Biotechnology Inc ROCO:6610
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TWi Biotechnology Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-10.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of NT$-10.00 Mil mean?
TWi Biotechnology (ROCO:6610) has a Payments of Debt of NT$-10.00 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on TWi Biotechnology and its competitors.
Is TWi Biotechnology's Payments of Debt too high?
TWi Biotechnology's current Payments of Debt is NT$-10.00 Mil. Overall, TWi Biotechnology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does TWi Biotechnology's Payments of Debt compare to VRTX and REGN?
TWi Biotechnology's Payments of Debt of NT$-10.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on TWi Biotechnology and its competitors. TWi Biotechnology's current Payments of Debt is NT$-10.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TWi Biotechnology stock overvalued right now?
TWi Biotechnology (ROCO:6610) has a current Payments of Debt of NT$-10.00 Mil. The current Payments of Debt is NT$-10.00 Mil. TWi Biotechnology's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For TWi Biotechnology (ROCO:6610), the current Payments of Debt is NT$-10.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TWi Biotechnology Business Description

Address Lane 221, Kang Chien Road, 8th Floor, Number 41, Neihu District, Taipei, TWN, 11494
TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs for unmet medical needs, particularly in the diseases associated with innate immunity. The pipeline products of the company comprise AC-201, AC-203, and AC-701.
31GF Score

Get the complete analysis for ROCO:6610

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.55
Price